Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial
- 1 December 2010
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 69 (12) , 2125-2130
Abstract
Objectives To study the efficacy of rescue treatment strategies and outcomes in patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) not achieving remission with first-line induction with corticosteroids (CS) and intravenous cyclophosphamide (CYC). Methods 159 eligible patients in the Wegener's Granulomatosis-Entretien (WEGENT) trial newly diagnosed with systemic or renal WG or MPA with ≥1 poor prognosis factors were included in this prospective study. Rescue treatment strategies and outcomes in patients with induction-refractory disease were analysed and patient characteristics at diagnosis were compared with those of induction-responders. Results Most patients (n=126, 79.2%) achieved remission; 1 stopped induction because of allergy and 32 were induction-refractory (24 WG and 8 MPA); 11 died rapidly within a median of 2.5 months, 6 of uncontrolled disease, 1 of an infectious complication and 4 of both. Treatment was discontinued in 1 patient with MPA with end-stage renal disease. Induction was switched to oral CYC in 20 patients, combined with infliximab in 1; 15 (75%) achieved remission or low disease activity state, 3 subsequently died of uncontrolled disease and 2 entered remission using several other agents including biological agents. Alveolar haemorrhage and a creatinine level >200 μmol/l were independently associated with induction-refractory disease. Among patients with induction-refractory disease, massive alveolar haemorrhage was associated with higher mortality. Conclusion Switching to oral CYC can be an effective rescue treatment for patients with systemic forms of WG or MPA who fail to achieve remission with first-line CS and intravenous CYC. However, a more rapidly effective regimen remains to be identified for most severely affected patients whose outcomes can be rapidly fatal.Keywords
This publication has 44 references indexed in Scilit:
- Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody–associated small‐vessel vasculitis: Comparison of two independent cohortsArthritis & Rheumatism, 2008
- BSR and BHPR guidelines for the management of adults with ANCA associated vasculitisRheumatology, 2007
- Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal VasculitisJournal of the American Society of Nephrology, 2007
- Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamideAnnals of the Rheumatic Diseases, 2007
- EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnnals of the Rheumatic Diseases, 2007
- Clinical Efficacy of Intravenous Immunoglobulin for Patients with MPO-ANCA-Associated Rapidly Progressive GlomerulonephritisNephron Clinical Practice, 2005
- Predicting mortality in systemic Wegener's granulomatosis: A survival analysis based on 93 patientsArthritis Care & Research, 2004
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence Data1973